̶ Exelixis will make upfront payment and contribute research funding for option to in-license at Investigational New Drug (IND) filing ̶ ALAMEDA, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)- ...
- Lantern will evaluate and potentially develop ADC programs with novel patent protected linkers, drug payloads and conjugation processes from Califia that have demonstrated enhanced, highly targeted ...
ZURICH, SWITZERLAND, May 5, 2025 --VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.
VERAXA Biotech AG, a developer of innovative cancer therapies, has announced a partnership with OmniAb, Inc. to create a bispecific antibody drug conjugate (bsADC) program aimed at treating solid ...
- Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia - Actimab-A selected for National Cancer Institute's recently opened ...
CHEYNEY, Pa., March 28, 2022 /PRNewswire/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, will be presenting new preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback